TerraPower Isotopes, a subsidiary of Bill Gates' nuclear company TerraPower, announced plans to construct a $450 million actinium-225 production facility in Philadelphia. The factory is scheduled to begin operations in 2029, marking a significant investment in medical radioisotope manufacturing.
Actinium-225 is a rare radioactive isotope used in targeted alpha therapy for treating certain cancers. The radioisotope attaches to cancer cells and delivers precise radiation doses while minimizing damage to healthy tissue. Current global supply of actinium-225 is extremely limited, creating bottlenecks for cancer treatment research and patient access.